City Therapeutics, Inc. (NASDAQ:CTY)
| Market Cap | 201.93M-8.6% |
| Revenue (ttm) | 6.49B-22.4% |
| Net Income | 1.80B-1.4% |
| EPS | 0.00 |
| Shares Out | 9.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 343,835 |
| Open | 20.62 |
| Previous Close | 20.77 |
| Day's Range | 20.03 - 21.14 |
| 52-Week Range | 19.75 - 23.88 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
CITY THERAPEUTICS, INC. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
About CTY
City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference (RNAi) therapeutics. The company is based in Cambridge, MA. The company engineers potent, specific, and durable RNAi trigger molecules combined with precision targeting ligands to deliver siRNAs beyond the liver to tissues such as ocular and central nervous system targets. Its R&D pipeline includes programs addressing thromboembolic diseases (targeting Factor XI), Stargardt disease (targeting RBP4), and other hepatic, ocular, and CNS conditions. Lead candidates include CITY-FXI, designed to prevent blood clots with reduced bleeding risk, and CITY-RBP4, aimed at slowing or halting vision loss in Stargardt disease. The company was founded by Ari Nowacek, John M. Maraganore. Andrew C. Orth has been the CEO of the company since 2025.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CTY stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CTY holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CTY's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CTY Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CTY patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CTY from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CTY
| ETF | Est. Holding Size |
|---|---|
| TDNAT. Rowe Price Biotech ETF | $17.43K |
Estimated from each fund’s disclosed top holdings × AUM
CTY Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CTY’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score